India Ratings has revised the outlook on Glenmark Pharmaceuticals' long-term bank facilities to Positive from Stable, affirming a rating of 'IND AA', following an exclusive licensing agreement expected to yield $700 million upfront and additional milestone payments of up to $1.225 billion.